Unprecedented exploration generates most comprehensive map of cancer genomes charted to date
Pan-Cancer Project discovers causes of previously unexplained cancers, pinpoints cancer-causing events and zeroes in on mechanisms of development
An international team has completed the most comprehensive study of whole cancer genomes to date, significantly improving our fundamental understanding of cancer and signposting new directions for its diagnosis and treatment.
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Project (PCAWG)*, known as the Pan-Cancer Project, a collaboration involving more than 1,300 scientists and clinicians from 37 countries, analysed more than 2,600 genomes of 38 different tumour types, creating a huge resource of primary cancer genomes. This was then the launch-point for 16 working groups studying multiple aspects of cancer’s development, causation, progression and classification.
Previous studies focused on the 1 per cent of the genome that codes for proteins, analogous to mapping the coasts of the continents. The Pan-Cancer Project explored in considerably greater detail the remaining 99 per cent of the genome, including key regions that control switching genes on and off — analogous to mapping the interiors of continents versus just their coastlines.
The Pan-Cancer Project has made available a comprehensive resource for cancer genomics research, including the raw genome sequencing data, software for cancer genome analysis, and multiple interactive websites** exploring various aspects of the Pan-Cancer Project data.
The Pan-Cancer Project extended and advanced methods for analysing cancer genomes which included cloud computing, and by applying these methods to its large dataset, discovered new knowledge about cancer biology and confirmed important findings of previous studies. In 23 papers published today (5th February) in Nature and its affiliated journals, the Pan-Cancer Project reports that:
- The cancer genome is finite and knowable, but enormously complicated. By combining sequencing of the whole cancer genome with a suite of analysis tools, we can characterise every genetic change found in a cancer, all the processes that have generated those mutations, and even the order of key events during a cancer’s life history.
- Researchers are close to cataloguing all of the biological pathways involved in cancer and having a fuller picture of their actions in the genome. At least one causal mutation was found in virtually all of the cancers analysed and the processes that generate mutations were found to be hugely diverse — from changes in single DNA letters to the reorganization of whole chromosomes. Multiple novel regions of the genome controlling how genes switch on and off were identified as targets of cancer-causing mutations.
- Through a new method of “carbon dating,” Pan-Cancer researchers discovered that it is possible to identify mutations which occurred years, sometimes even decades, before the tumour appears. This opens, theoretically, a window of opportunity for early cancer detection.
- Tumour types can be identified accurately according to the patterns of genetic changes seen throughout the genome, potentially aiding the diagnosis of a patient’s cancer where conventional clinical tests could not identify its type. Knowledge of the exact tumour type could also help tailor treatments.
“The findings we have shared with the world today are the culmination of an unparalleled, decade-long collaboration that explored the entire cancer genome. With the knowledge we have gained about the origins and evolution of tumours, we can develop new tools and therapies to detect cancer earlier, develop more targeted therapies and treat patients more successfully.”
Dr. Lincoln Stein, member of the project steering committee and Head of Adaptive Oncology at the Ontario Institute for Cancer Research (OICR)
“This work is helping to answer a long-standing medical difficulty, why two patients with what appear to be the same cancer can have very different outcomes to the same drug treatment. We show that the reasons for these different behaviours are written in the DNA. The genome of each patient’s cancer is unique, but there are a finite set of recurring patterns, so with large enough studies we can identify all these patterns to optimize diagnosis and treatment.”
“This study provides the most complete picture to date of cancer-causing mutations in all parts of the genome. It was a massive team science effort involving researchers spanning the globe. At UC Santa Cruz, our strengths in systems biology and RNA expression helped us connect findings in the previously unexplored noncoding genome with the pathways that lead to cancer. Like a charted map, this new work creates a reference and resource that researchers can use to interpret future data and physicians can use to guide treatment.”
Steering committee member Josh Stuart, a professor of biomolecular engineering at UC Santa Cruz
”With the continuing drop in sequencing costs and accumulation of genomic data across increasing numbers of patients worldwide, the comprehensive analyses performed in this project will serve as a template for future work and will enable new discoveries in cancer.”
Steering committee member, Dr. Gad Getz, professor of pathology at the Massachusetts General Hospital and the Broad Institute of MIT and Harvard
“This huge international study was only possible due to the work and collaboration of more than a thousand researchers and clinicians across the world, and I would like to thank everyone involved.”
Steering committee member Dr. Jan Korbel from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany
“The completion of this project represents the culmination of more than a decade of ground-breaking work in studying the cancer genome. When we launched ICGC in 2007, an initiative of this magnitude was unprecedented. I am thrilled that the scientific community has come together to produce this comprehensive study, which enhances our understanding of cancer and fosters the development of new medicines for cancer patients.”
Dr. Tom Hudson, Chief Scientific Officer at AbbVie and a founder of the International Cancer Genome Consortium
“ICGC’s latest initiative called ARGO (Accelerating Research in Genomic Oncology) is about the patient, with the goal of delivering to the world 1 million patient-years of precision oncology knowledge to improve human health. This data must be shared across traditional jurisdictional boundaries to realize the full impact of precision medicine, for the benefit of all.”
Andrew Biankin AO, Regius Professor of Surgery and Director of the Wolfson Wohl Cancer Research Centre at the University of Glasgow, and Executive Director, International Cancer Genome Consortium.
“Using the data and infrastructure created by The Cancer Genome Atlas (TCGA) as a blueprint, PCAWG has further improved our understanding of cancer and strengthened our ability to develop successful, international projects of this scale.”
Jean Claude Zenklusen, Ph.D., director of TCGA Program Office at the National Cancer Institute (NCI)
“In addition to benefiting the cancer research field, this collaboration also honors the many patients who donated samples to TCGA – turning their finite gift of tissue into data that can be used infinitely.”
Carolyn Hutter, Ph.D., National Human Genome Research Institute team lead for TCGA
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. (2020) Pan-cancer analysis of whole genomes. Nature. DOI: 10.1038/s41586-020-1969-6
The Nature collection landing page with all Pan-Cancer publications will go live when the papers publish: https://www.nature.com/collections/pcawg/
Further information on the Pan-Cancer Project:
* ICGC – International Cancer Genome Consortium https://icgc.org/; TCGA – The Cancer Genome Atlas (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga)
** PCAWG Portal (dcc.icgc.org/pcawg); UCSC Xena (pcawg.xenahubs.net); Expression Atlas (www.ebi.ac.uk/gxa/home); PCAWG-Scout (pcawgscout.bsc.es); Chromothripsis Explorer (compbio.med.harvard.edu/chromothripsis)
ICGC – International Cancer Genome Consortium (https://icgc.org/)
TCGA – The Cancer Genome Atlas (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga)
PCAWG – PanCancer Analysis of Whole Genomes (dcc.icgc.org/pcawg)
UCSC – University of California Santa Cruz (pcawg.xenahubs.net)
Expression Atlas (www.ebi.ac.uk/gxa/home)
Chromothripsis Explorer (compbio.med.harvard.edu/chromothripsis)
The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; we share our data, results, tools and technologies across the world to advance science. Our findings are used to improve health and to understand life on Earth. Find out more at www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog.
OICR is a collaborative, not-for-profit research institute funded by the Government of Ontario. We conduct and enable high-impact translational cancer research to accelerate the development of discoveries for patients around the world while maximizing the economic benefit of this research for the people of Ontario. For more information visit www.oicr.on.ca.
Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff, and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to https://www.broadinstitute.org.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $1 billion and comprises more than 8,500 researchers working across more than 30 institutes, centers and departments. In August 2019 the MGH was once again named #2 in the nation by U.S. News & World Report in its list of “America’s Best Hospitals.”
EMBL is Europe’s flagship laboratory for the life sciences. We are an intergovernmental organisation established in 1974 and are supported by over 20 member states. EMBL performs fundamental research in molecular biology, studying the story of life. We offer services to the scientific community; train the next generation of scientists and strive to integrate the life sciences across Europe.
We are international, innovative and interdisciplinary. We are more than 1600 people, from over 80 countries, operating across six sites in Grenoble (France), Hamburg (Germany), Heidelberg (Germany), Cambridge (UK), Rome (Italy), and Barcelona (Spain). Our scientists work in independent groups and conduct research and offer services in all areas of molecular biology. Our research drives the development of new technology and methods in the life sciences. We work to transfer this knowledge for the benefit of society. For more information, visit www.embl.de.
UC Santa Cruz is a public university combining the intimacy of a small, liberal arts college with the depth and rigor of a major research university. The UC Santa Cruz Genomics Institute creates advanced technologies and open-source genomics platforms to unravel evolutionary patterns, molecular processes, and the underpinnings of disease. The Genomics Institute’s platforms, technologies and scientists unite global communities to create and deploy data-driven, life-saving treatments and innovative environmental and conservation efforts. For more information, visit www.ucsc.edu and genomics.ucsc.edu.
About The National Cancer Institute and The National Human Genome Research Institute, National Institutes of Health
The National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), jointly manage The Cancer Genome Atlas (TCGA), a landmark cancer genomics program. For more information about TCGA, visit https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga
NCI leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information, visit the NCI website at https://www.cancer.gov or call NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
NHGRI is one of the 27 institutes and centers at the National Institutes of Health. The NHGRI Extramural Research Program supports grants for research and training and career development at sites nationwide. Additional information about NHGRI can be found at http://www.genome.gov
As one of the top 100 of the world’s universities, we deliver world-class, world-changing research and education with impact. We are a member of the prestigious Russel Group of leading UK Universities with annual research income of more than £179m. We’re currently investing £1 billion in our estate to create spaces and opportunities that will allow us to remain at the forefront of change excellence and innovation. Information about ICGC-ARGO can be found at www.icgc-argo.org.
12 Apr 2021
New genetic drug target for treatment resistant colorectal cancer
Researchers have identified a new potential drug target for treating some types of advanced colorectal cancers.
7 Apr 2021
‘Patchwork’ tumours prevalent across multiple cancer types
Scientists have confirmed that tumour evolution is driven by changes that benefit the cancer, and these lead to a wide range ...